Top 10 exphem.org Competitors

iseh.org

This week on Simply Blood, we sat down with the ISEH 2026 President, Michael Milsom (DKFZ and HI-STEM, Germany), to share what's ahead for ISEH. Dr. Milsom shares insights into upcoming strategic initiatives, the importance of the ISEH community, promising new research, updates on Experimental Hematology, and more. Watch the interview to discover the exciting things to come for your society.        Blog post contributed by John Crispino, PhD, MBA of the ISEH Publications...

cibmtr.org

the center for international blood and marrow transplant research (cibmtr) is a collaborative resource of data and experts supporting research in cellular therapies to improve patient outcomes.

oncohemakey.com

Fastest Oncology & Hematology Insight Engine

stemcell.ucla.edu

Take the elevator up to the 14th floor of the Factor Building at UCLA and you’ll find two things: striking views of the greater San Fernando Valley — marine layer permitting — and scientists covered head-to-toe in protective gear transforming scientific discoveries into new, innovative cell therapies.

techtransfer.cancer.gov

Attend a free NIH webinar to learn about a potential novel treatment for Retinitis Pigmentosa (RP), an eye disorder. Dr. Patricia Becerra at the National Eye Institute developed pigment epithelium-derived factor (PEDF) peptide, a novel therapeutic. Attend to learn about the technology and how to develop and commercialize it.

mva.org

Frequently asked questions about MVA. Get to know our strategic initiatives and many different projects and find out the benefits of being a member of MVA.

ehoonline.biomedcentral.com

The human CD19 antigen is a 95 kd transmembrane glycoprotein belonging to the immunoglobulin superfamily. CD19 is classified as a type I transmembrane protein, with a single transmembrane domain, a cytoplasmic C-terminus, and extracellular N-terminus. CD19 is a biomarker for normal and neoplastic B cells, as well as follicular dendritic cells. CD19 is critically involved in establishing intrinsic B cell signaling thresholds through modulating both B cell receptor-dependent and independent signaling. CD19 functions as the dominant signaling component of a multimolecular complex on the surface of mature B cells, alongside complement receptor CD21, and the tetraspanin membrane protein CD81 (TAPA-1), as well as CD225. Through study of CD19 transgenic and knockout mouse models, it becomes clear that CD19 plays a critical role in maintaining the balance between humoral, antigen-induced response and tolerance induction. This review also summarized latest clinical development of CD19 antibodies, anti-B4-bR (an immunotoxin conjugate), blinatumomab (BiTE), and SAR3419 (huB4-DM4), a novel antibody-drug conjugate.

pubmed.ncbi.nlm.nih.gov

Gates Foundation, St Jude Children's Research Hospital.